Latest News

Bristol-Myers Squibb’s Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial


PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BristolMyers–Bristol-Myers Squibb’s Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

Source link




Related posts

New vaccine shows promise against chikungunya virus

Newsemia

Policy communities post-devolution? spatial planning and the British Irish Council

Newsemia

U.S. Set to Break Measles Cases Record

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy